A broad coalition of artificial intelligence leaders, biotechnology executives, scientists, public health experts and former national security officials has called on Congress to establish mandatory federal safeguards governing the sale and production of synthetic DNA and RNA. The group, which includes leaders from OpenAI, Google DeepMind, Anthropic and Microsoft AI, argues that advances in AI are rapidly increasing the need for stronger biosecurity measures. In a letter to lawmakers, the signatories warned that while synthetic biology has enabled major breakthroughs in medicine and research, the same technologies could potentially be misused if adequate oversight is not in place.
Synthetic DNA and RNA are widely used throughout the life sciences industry, supporting the development of vaccines, gene therapies, biologics and other advanced medical technologies. Historically, the industry has relied on voluntary safeguards developed by organizations such as the International Gene Synthesis Consortium, which was formed to reduce the risk of misuse by screening orders and monitoring potentially dangerous genetic sequences. However, the coalition argues that voluntary standards may no longer be sufficient as AI systems become increasingly capable of assisting with complex biological research and lowering technical barriers that previously limited access to sophisticated biological knowledge.
The group is urging lawmakers to require providers of synthetic DNA, RNA and synthesis equipment to verify customer identities, screen orders for sequences of concern and maintain detailed records that could support future investigations. They argue that many responsible companies already follow these practices voluntarily, but a federal framework would create consistent standards across the industry and prevent gaps that could be exploited by malicious actors. The proposal also seeks to ensure that manufacturers of DNA synthesis machines are subject to similar requirements, recognizing that advances in technology are making genetic synthesis more accessible and distributed.
The request comes amid growing attention to the intersection of AI and biotechnology. As AI models become more capable in scientific reasoning and biological research, experts increasingly see both tremendous opportunities and potential risks. Supporters of the proposed legislation emphasize that stronger oversight is intended not to slow innovation but to preserve public trust and ensure that advances in synthetic biology continue to be developed responsibly. More broadly, the effort reflects a growing recognition that emerging technologies in AI and life sciences may require new regulatory frameworks to address challenges that span both digital and biological domains.
Click here to read the original news story.
